Press the print button on your browser.
Click here to return to the previous page.
Quality Measures for 2008 PQRI
The 119 quality measures included in the 2008 PQRI program are listed below. The measures are sorted alphabetically by disease/condition. For each measure that you feel might be applicable to your practice, click on any of the three PDF documents listed to the right of the measure for additional information.
(an * indicates that a document has been revised since the initial posting)
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Quality Measures Documents Acute Bronchitis
#116. Inappropriate antibiotic treatment for adults with acute bronchitis Acute Myocardial Infarction
#28. Aspirin at arrival for acute myocardial infarction (AMI) Acute Otitis Externa (AOE)
#91. Topical therapy #92. Pain assessment #93. Systemic antimicrobial therapy – avoidance of inappropriate use Asthma
#53. Pharmacologic therapy #64. Asthma assessment Cancer
Non-Specific
#73. Plan for chemotherapy documented before chemotherapy administered Breast Cancer
#71. Hormonal therapy for stage IC-III, ER/PR positive breast cancer #74. Radiation therapy recommended for invasive breast cancer patients who have undergone breast conserving surgery Chronic Lymphocytic Leukemia
#70. Baseline flow cytometry Colon Cancer
#72. Chemotherapy for stage III colon cancer patients Multiple Myeloma
#69. Treatment with bisphosphonates Myelodysplastic Syndrome (MDS)
#68. Documentation of iron stores in patients receiving erythropoietin therapy Myelodysplastic Syndrome (MDS) & Acute Leukemias
#67. Baseline cytogenetic testing performed on bone marrow Prostate Cancer
#101. Appropriate initial evaluation of patients with prostate cancer #102. Inappropriate use of bone scan for staging low-risk prostate cancer patients #103. Review of treatment options in patients with clinically localized prostate cancer #104. Adjuvant hormonal therapy for high-risk prostate cancer patients #105. Three-dimensional radiotherapy for patients with prostate cancer Chest Pain (Non-traumatic)
#54. Electrocardiogram performed for non-traumatic chest pain Chronic Kidney Disease (CKD)
#120. ACE inhibitor or Angiotensin Receptor Blocker (ARB) therapy in patients with CKD #121. Laboratory testing (calcium, phosphorus, intact parathyroid hormone (iPTH) and lipid profile) #122. Blood pressure management #123. Plan of care - elevated hemoglobin for patients receiving erythropoiesis-stimulating agents (ESA) Chronic Obstructive Pulmonary Disease (COPD)
#51. Spirometry evaluation #52. Bronchodilator therapy Community-Acquired Bacterial Pneumonia
#56. Vital signs for community-acquired bacterial pneumonia #57. Assessment of oxygen saturation for community-acquired bacterial pneumonia #58. Assessment of mental status for community-acquired bacterial pneumonia #59. Empiric antibiotic for community acquired-bacterial pneumonia Coronary Artery Disease
#06. Oral antiplatelet therapy prescribed for patients with coronary artery disease #07. Beta-blocker therapy for coronary artery disease patients with prior myocardial infarction #118. Angiotensin converting enzyme inhibitor (ACE) or angiotensin receptor blocker (ARB) therapy for patients with coronary artery disease and diabetes and/or left ventricular systolic dysfunction (LVSD) Critical Care
#75. Prevention of ventilator-associated pneumonia – head elevation #76. Prevention of catheter-related bloodstream infections (CRBSI) – central venous catheter insertion protocol Depression – Major Depressive Disorder
#09. Antidepressant medication during acute phase for patients with new episode disease of major depression #106. Patients who have major depression disorder who meet DSM IV criteria #107. Patients who have major depression disorder who are assessed for suicide risks Diabetes Mellitus
#01. Hemoglobin A1c poor control in Type 1 or 2 diabetes mellitus #02. Low density lipoprotein control in Type 1 or 2 diabetes mellitus #03. High blood pressure control in Type 1 or 2 diabetes mellitus #117. Dilated eye exam in diabetic patient #119. Urine screening for microalbumin or medical attention for nephropathy in diabetic patients #126. Diabetic foot and ankle care, peripheral neuropathy: neurological evaluation #127. Diabetic foot and ankle care, ulcer prevention: evaluation of footwear End Stage Renal Disease (ESRD)
#78. Vascular access for patients undergoing hemodialysis #79. Influenza vaccination in patients with end stage renal disease #80. Plan of care for ESRD patients with anemia #81. Plan of care for inadequate hemodialysis in ESRD patients #82. Plan of care for inadequate peritoneal dialysis Eye Care
Age-Related Macular Degeneration
#14. Dilated macular examination Diabetic Retinopathy
#18. Documentation of presence or absence of macular edema and level of severity of retinopathy #19. Communication with the physician managing ongoing diabetes care Primary Open Angle Glaucoma
#12. Optic nerve evaluation Gastroesophageal Reflux Disease (GERD)
#77. Assessment of GERD symptoms in patients receiving chronic medication for GERD Geriatric Care
#04. Screening for future fall risk #46. Medication reconciliation #47. Advance care plan Health Information Technology (HIT)
#124. Adoption/use of health information technology (electronic health records) #125. Adoption/use of e-prescribing Heart Failure
#05. Angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy for left ventricular systolic dysfunction (LVSD) #08. Beta-blocker therapy for left ventricular systolic dysfunction Hepatitis C
#83. Testing of patients with chronic hepatitis C (HCV) for hepatitis C viremia #84. Initial hepatitis C RNA testing #85. HCV genotype testing prior to therapy #86. Consideration for antiviral therapy in HCV patients #87. HCV RNA testing at week 12 of therapy #88. Hepatitis A and B vaccination in patients with HCV #89. Counseling patients with HCV regarding use of alcohol #90. Counseling of patients regarding use of contraception prior to starting antiviral therapy Osteoarthritis
#109. Patients with osteoarthritis who have an assessment of their pain and function Osteoporosis
#24. Communication with the physician managing ongoing care post-fracture #39. Screening or therapy for osteoporosis for women aged 65 years and older #40. Management following fracture #41. Pharmacologic therapy Otitis Media with Effusion (OME)
#94. Diagnostic evaluation – assessment of tympanic membrane mobility #95. Hearing testing #96. Antihistamines or decongestants – avoidance of inappropriate use #97. Systemic antimicrobials – avoidance of inappropriate use #98. Systemic corticosteroids – avoidance of inappropriate use Pathology
#99. Breast cancer patients who have a pT and pN category and histologic grade for their cancer #100. Colorectal cancer patients who have a pT and pN category and histologic grade for their cancer Perioperative Care
#20. Timing of antibiotic prophylaxis - Ordering physician #21. Selection of prophylactic antibiotic - First OR second generation cephalosporin #22. Discontinuation of prophylactic antibiotics (Non-cardiac procedures) #23. Venous thromboembolism (VTE) prophylaxis (When indicated in ALL patients) #30. Timing of prophylactic antibiotics - Administering physician #45. Discontinuation of prophylactic antibiotics (Cardiac procedures) Coronary Artery Bypass Graft (CABG)
#43. Use of internal mammary artery (IMA) in CABG surgery #44. Pre-operative beta-blocker in patients with isolated CABG surgery Preventive Care and Screening
#110. Influenza vaccination for patients ≥ 50 years old #111. Pneumonia vaccination for patients 65 years and older #112. Screening mammography #113. Colorectal cancer screening #114. Inquiry regarding tobacco use #115. Advising smokers to quit Pharyngitis
#66. Appropriate testing for children with pharyngitis Rheumatoid Arthritis
#108. Disease modifying anti-rheumatic drug therapy in rheumatoid arthritis Stroke and Stroke Rehabilitation
#31. Deep vein thrombosis (DVT) prophylaxis for ischemic stroke or intracranial hemorrhage #32. Discharged on antiplatelet therapy #33. Anticoagulant therapy prescribed for atrial fibrillation at discharge #34. Tissue plasminogen activator (t-PA) considered #35. Screening for dysphagia #36. Consideration of rehabilitation services Stroke and Stroke Rehabilitation - Radiology
#10. Computed tomography (CT) or magnetic resonance imaging (MRI) reports #11. Carotid imaging reports Syncope
#55. Electrocardiogram performed for syncope Upper Respiratory Infection (URI)
#65. Appropriate treatment for children with upper respiratory infection Urinary Incontinence
#48. Assessment of presence or absence of urinary incontinence in women aged 65 years and older #49. Characterization of urinary incontinence in women aged 65 years and older #50. Plan of care for urinary incontinence in women aged 65 years and older Measures Applicable to Health Care Professionals Other than MD/DO Physicians
#128. Universal weight screening and follow-up #129. Universal influenza vaccine screening and counseling #130. Universal documentation and verification of current medications in the medical record #131. Pain assessment prior to initiation of patient treatment #132. Patient co-development of treatment plan/plan of care #133. Screening for cognitive impairment #134. Screening for clinical depression |
Many of the measures in the PQRI were developed by the AMA-convened Physician Consortium for Performance Improvement®, in collaboration with the National Committee for Quality Assurance (NCQA) and/or a medical specialty society. For additional information on the Consortium including additional background information on the quality measures with both the rationale and evidence base for each measure, please visit www.physicianconsortium.org.
For additional information on NCQA and NCQA measures, please visit www.ncqa.org.
Questions: For additional information on the PQRI program, please visit the CMS Web site at http://www.cms.hhs.gov/pqri.
Content provided by: Rick Crosslin